Neutrophil to lymphocyte ratio predicts prognosis in unresectable pancreatic cancer

Abstract

Inflammation-based prognostic indicators have been developed to predict the prognosis in patients with pancreatic cancer. However, prognostic indices have not been established in patients with unresectable pancreatic cancer, including those without indication for chemotherapy at diagnosis. This study aimed to identify the predictors in all patients with unresectable pancreatic cancer. We retrospectively analyzed data of 119 patients with unresectable pancreatic cancer from June 2006 to September 2018. The following laboratory parameters were evaluated: the Glasgow Prognostic Score (GPS), modified GPS, neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), C-reactive protein albumin (CRP/Alb) ratio, and prognostic nutritional index (PNI). We performed time-dependent receiver operating characteristic analysis, overall survival (OS) analysis, and univariate and multivariate analyses to determine the prognostic factors in patients with unresectable pancreatic cancer. The cut-off value for NLR was determined to be 3.74. The 6-month OS rates in low and high NLR groups were 75.5% and 18.8% (P < 0.001). In the univariate analysis, advanced age (P = 0.003), metastatic pancreatic cancer (P = 0.037), no treatment (P < 0.001), worse Eastern Cooperative Oncology Group Performance Status (ECOG-PS) (P < 0.001), high GPS (P < 0.001), high modified GPS (P < 0.001), high NLR (P < 0.001), high PLR (P = 0.002), high CRP/Alb ratio (P < 0.001), and low PNI (P < 0.001) were identified as the prognostic factors. The multivariate analysis revealed that metastatic pancreatic cancer (P = 0.046), no treatment (P < 0.001), worse ECOG-PS (P = 0.002), and high NLR (P < 0.001) were independently associated with OS. We revealed that the high NLR could be an independent indicator of poor prognosis in patients with unresectable pancreatic cancer.

Introduction

Pancreatic cancer is one of the most aggressive types, with 5-year overall survival (OS) rate < 10%^1,2. Due to the difficulty in early detection, most patients present with unresectable disease, and less than 30% of patients have resectable tumors when diagnosed³. Intensive chemotherapy regimens such as FOLFIRINOX and Gem plus nab-paclitaxel has been developed^4,5, however, the median OS was 8.5–11.1 months in these clinical trials.

Recently, inflammation has been reported to be closely related to carcinogenesis and progression of pancreatic cancer⁶. In clinical settings, systemic inflammation-based prognostic indicators have been developed to predict the prognosis in patients with pancreatic cancer. Among laboratory parameters, the modified Glasgow Prognostic Score (GPS)^7,8, neutrophil-to-lymphocyte ratio (NLR)^9–13, platelet-to-lymphocyte ratio (PLR)¹⁴, C-reactive protein albumin (CRP/Alb) ratio^15,16, and prognostic nutritional index (PNI)¹⁷, have been reported to be predictive factors of OS in patients with pancreatic cancer. The subjects in most of the previous studies were the patients who underwent surgical resection or chemotherapy. However, in a real-world setting, some patients with unresectable pancreatic cancer have no indication for chemotherapy at diagnosis because of advanced age, or worse, their general condition. Thus, it is important to establish precise prognostic biomarkers in all patients with unresectable pancreatic cancer.

In this study, our goal is to identify the prognostic predictors in patients with unresectable pancreatic cancer, and to evaluate the corresponding laboratory parameters. To this end, we retrospectively evaluated the patient laboratory parameters.

Results

Patient characteristics

Table 1 shows the characteristics of the 119 patients in this study. The data for 119 patients with unresectable pancreatic cancer were evaluated. The median age was 73 years old (range 43–94), and median follow-up day was 136 days (range 4–1252). During follow-up, 116 patients died. Of the enrolled patients, 52.9% were male, and 28.6% had Eastern Cooperative Oncology Group Performance Status (ECOG-PS) ≥ 2. Regarding the tumor lesion, 40.3% were located in the head, and 88.2% were diagnosed as metastatic pancreatic cancer. Regarding the treatment, 31.9% received best supportive care (BSC), 7.6% underwent chemoradiotherapy, and 60.5% underwent chemotherapy. In patients receiving BSC, the median age was 82.0 years old (range 53–94), and 36.8% opted for BSC because of the advanced age itself.

Table 1.

Patient characteristics.

No. of patients	119
Age (years), median (range)	73	(43–94)
Follow-up (day), median (range)	136	(4–1252)
Total of deaths	116
Body mass index, median (range)	20.56	(15.11–30.25)
Gender, n (%)
Male	63	(52.9)
Female	56	(47.1)
ECOG-PS, n (%)
< 1	84	(70.6)
≥2	34	(28.6)
Unknown	1	(0.8)
Location, n (%)
Head	48	(40.3)
Body or tail	71	(59.7)
Stage, n (%)
Locally advanced	14	(11.8)
Metastatic	105	(88.2)
Treatment, n (%)
Best Supportive Care	38	(31.9)
Chemoradiotherapy	9	(7.6)
Chemotherapy	72	(60.5)
FOLFIRINOX	18	(15.1)
Gem + nabPTX	6	(5.0)
Gem + S1	7	(5.9)
Gem + elrotinib	1	(0.8)
Gem	40	(33.6)
GPS, (0:1:2:unknown)	42:42:33:2
modified GPS, (0:1:2:unknown)	50:34:33:2
NLR, median (range)	4.32	(1.00–39.97)
PLR, median (range)	179.40	(38.50–655.41)
CRP/Alb ratio	0.41	(0.004–12.34)
PNI median, (range)	43.44	(24.25–61.96)

ECOG-PS Eastern Cooperative Oncology Group Performance Status; GPS Glasgow Prognostic Score; NLR neutrophil-to-lymphocyte ratio; PLR platelet-to-lymphocyte ratio; CRP C-reactive protein; Alb albumin; PNI prognostic nutritional index.

NLR is a useful prognostic marker in patients with unresectable pancreatic cancer

Table 2 shows the area under the curve (AUC) for OS variables using time-dependent receiver operating characteristic (ROC) curve at the 6-month follow-up. NLR had the highest value (0.792) among the prognostic factors. Figure 1A–F show the relationship between the prognostic factors and OS. The cut-off values for NLR, PLR, CRP/Alb ratio, and PNI were determined as 3.74, 146, 0.28, and 46.8, respectively. A lower GPS, modified GPS, NLR, PLR, and CRP/Alb ratio were significantly associated with a higher OS. While, a higher PNI was closely related to a higher OS (P < 0.001). The six-month OS rates in GPS0, GPS1, and GPS2 subgroups were 71.4%, 26.2%, and 24.2%, respectively, (P < 0.001; Fig. 1A), while those in the modified GPS0, modified GPS1, and modified GPS2 were 66.0%, 23.5%, and 24.2%, respectively, (P < 0.001; Fig. 1B). The 6-month OS rates in the low and high NLR groups were 75.5% and 18.8%, respectively, (P < 0.001; Fig. 1C), while those in the low and high PLR groups were 60.5% and 33.7%, respectively, (P = 0.002; Fig. 1D). The 6-month OS rates in the low and high CRP/Alb groups were 67.3% and 23.5%, respectively, (P < 0.001; Fig. 1E), while those in the high and low PNI groups were 70.0% and 28.2%, respectively, (P < 0.001; Fig. 1F).

Table 2.

AUC in variables for overall survival at 6-month follow-up.

	AUC	95% CI	P value
GPS	0.722	0.627–0.809	< 0.001
modified GPS	0.711	0.618–0.797	< 0.001
NLR	0.792	0.705–0.870	< 0.001
PLR	0.631	0.531–0.731	0.016
CRP/Alb ratio	0.753	0.661–0.839	< 0.001
PNI	0.719	0.623–0.806	< 0.001

AUC area under the curve; CI confidence interval; GPS Glasgow Prognostic Score; NLR neutrophil-to-lymphocyte ratio; PLR platelet-to-lymphocyte ratio; CRP C-reactive protein; Alb albumin; PNI prognostic nutritional index.

Figure 1.

The overall survival (OS) according to prognostic factors in patients with unresectable pancreatic cancer. GPS Glasgow Prognostic Score, NLR neutrophil to lymphocyte ratio, PLR platelet to lymphocyte ratio, CRP/Alb ratio C-reactive protein albumin ratio, PNI prognostic nutritional index.

High NLR is independently associated with OS

Table 3 shows univariate and multivariate analyses of the predictive factors of OS in patients with unresectable pancreatic cancer. In the univariate analysis, advanced age (hazard ratio [HR] = 1.035; 95% confidence interval [CI] 1.012–1.058; P = 0.003), metastatic pancreatic cancer (HR 1.819; 95% CI 1.036–3.196; P = 0.037), no treatment (HR 4.632; 95% CI 2.971–7.222; P < 0.001), worse ECOG-PS (HR 4.309; 95% CI 2.726–6.812; P < 0.001), GPS 2/1 (HR 3.637; 95% CI 2.215–5.973; P < 0.001/HR 2.228; 95% CI 1.424–3.487; P < 0.001), modified GPS 2/1 (HR 3.357; 95% CI 2.082–5.411; P < 0.001/HR 2.167; 95% CI 1.373–3.421; P = 0.001), high NLR (HR 3.363; 95% CI 2.251–5.025; P < 0.001), high PLR (HR 1.878; 95% CI 1.256–2.807; P = 0.002), high CRP/Alb ratio (HR 2.674; 95% CI 1.803–3.966; P < 0.001), and low PNI (HR 2.251; 95% CI 1.511–3.353; P < 0.001) were identified as prognostic factors. The multivariate analysis revealed that metastatic pancreatic cancer (HR 1.923; 95% CI 1.013–3.649; P = 0.046), no treatment (HR 5.635; 95% CI 3.076–10.325; P < 0.001), worse ECOG-PS (HR 2.466; 95% CI 1.410–4.313; P = 0.002), and high NLR (HR 2.430; 95% CI 1.484–3.977; P < 0.001) were independently associated with OS.

Table 3.

Univariate and multivariate analyses of prognostic factors in patients with unresectable pancreatic cancer.

	Univariate analysis			Multivariate analysis
	HR	95% CI	P value	HR	95% CI	P value
Age
Per year	1.035	1.012‐1.058	0.003
Gender
Female	1
Male	1.004	0.692‐1.457	0.982
Tumor location
Head	1
Body or tail	1.418	0.975‐2.062	0.068
cStage
Locally advanced	1			1
Metastatic	1.819	1.036‐3.196	0.037	1.923	1.013‐3.649	0.046
Treatment
Present	1			1
Absent	4.632	2.971‐7.222	< 0.001	5.635	3.076‐10.325	< 0.001
ECOG-PS
≤1	1			1
> 1	4.309	2.726–6.812	< 0.001	2.466	1.410–4.313	0.002
GPS
0	1
1	2.228	1.424–3.487	< 0.001
2	3.637	2.215–5.973	< 0.001
Modified GPS
0	1
1	2.167	1.373–3.421	0.001
2	3.357	2.082–5.411	< 0.001
NLR
≤3.74	1			1
> 3.74	3.363	2.251–5.025	< 0.001	2.430	1.484–3.977	< 0.001
PLR
≤146	1
> 146	1.878	1.256–2.807	0.002
CRP/Alb ratio
≤0.28	1
> 0.28	2.674	1.803–3.966	< 0.001
PNI
> 46.8	1
≤46.8	2.251	1.511–3.353	< 0.001

HR hazard ratio; CI confidence interval; ECOG-PS eastern cooperative oncology group; GPS Glasgow Prognostic Score; NLR neutrophil-to-lymphocyte ratio; PLR platelet-to-lymphocyte ratio; CRP C-reactive protein; Alb albumin; PNI prognostic nutritional index.

High NLR is associated with the metastatic stage, and worse performance status

Table 4 shows clinical parameters in relation to NLR. Patients in the higher NLR group were significantly associated with metastatic pancreatic cancer (P = 0.001). ECOG-PS was significantly higher in patients in the higher NLR group (P < 0.001). GPS, modified GPS, PLR, and CRP/Alb ratio were significantly higher in the higher NLR group (P < 0.001), while PNI was significantly lower in the higher NLR group (P < 0.001).

Table 4.

Clinical parameters in relation to NLR.

	NLR ≤ 3.74 (n = 49)	NLR > 3.74 (n = 69)	P value
Age, median (range)	72 (46–93)	74 (53–94)	0.512
Gender (female/male)	25/24	31/38	0.641
Tumor location (head/body or tail)	24/25	24/45	0.175
cStage (locally advanced/metastatic)	12/37	2/67	0.001
Treatment (present/absent)	38/11	43/26	0.120
ECOG-PS (≤ 1/ > 1)	44/5	40/29	< 0.001
GPS (0/1/2)	30/12/6	12/30/27	< 0.001
Modified GPS (0/1/2)	34/8/6	16/26/27	< 0.001
PLR, median (range)	128.10 (38.50–267.98)	202.01 (60.96–655.41)	< 0.001
CRP/Alb ratio, median (range)	0.06 (0.00–2.39)	0.87 (0.03–12.34)	< 0.001
PNI, median (range)	48.35 (34.60–61.96)	39.52 (24.25–51.51)	< 0.001

NLR neutrophil-to-lymphocyte ratio; GPS Glasgow Prognostic Score; PLR platelet-to-lymphocyte ratio; CRP C-reactive protein; Alb albumin; PNI prognostic nutritional index.

Discussion

In this study, we evaluated the prognostic factors in patients with unresectable pancreatic cancer, including those without indication for chemotherapy. This study revealed that the NLR was an independent prognostic factor in patients with unresectable pancreatic cancer, and superior to the GPS, modified GPS, PLR, CRP/Alb ratio, and PNI as the prognostic indicators.

Inflammation has been recently considered to play an essential role in cancer progression. Moreover, inflammation-based prognostic factors have been developed such as the GPS¹⁸, modified GPS¹⁹, PLR¹⁴, CRP/Alb ratio²⁰, and NLR²¹. NLR was originally established as the parameter of stress and systemic inflammation in clinical ICU practice²². Recently, NLR has been increasingly appreciated as a pivotal prognostic factor in various cancers^23,24. With regard to the pancreatic cancer, previous studies revealed that NLR was a significant prognostic marker among various disease stages^{9–13,25–30}. In resectable pancreatic cancer, previous studies have identified preoperative NLR as a useful prognostic marker^9,13. In particular, Stotz et al., using a multivariate Cox proportional-hazard model in their study, reported that advanced tumor stage and high NLR (NLR > 5) were independent prognostic factors for operable pancreatic cancers⁹. In unresectable pancreatic cancer, most of the previous studies investigated the role of NLR in patients undergoing chemoradiotherapy or chemotherapy^{10–12,25–27}. Some studies have illustrated that baseline NLR and post-chemotherapy changes in NLR values could predict OS in patients undergoing chemotherapy^12,26. However, few have evaluated the prognosis in patients with advanced pancreatic cancer, including those without treatment⁹. In this study, NLR was shown to be an independent prognostic index in patients with unresectable pancreatic cancer, both with and without treatment. In an increasingly aging society, it is possible that among patients without an indication for chemotherapy at the time of diagnosis, there would be an increasing number of those with unresectable pancreatic cancer. Indeed, more than 30% of the enrolled patients received BSC in this study. In addition, the median age was more than 80 years old in patients receiving BSC. Collectively, NLR at the time of diagnosis could be useful for prognosis prediction in unresectable pancreatic cancer in our aging society.

In this study, we revealed that PNI could also predict the prognosis as well as the inflammation-based prognostic factors in the log-rank test and univariate analysis. PNI was originally established as the surgical risk indicator in patients undergoing gastrointestinal surgery³¹. Recently, PNI was reported to be useful in predicting the prognosis in the patients undergoing surgery for pancreatic cancer^17,32. Our results suggested that nutritional status may be related to prognosis in patients with unresectable pancreatic cancer. Therefore, nutritional intervention may contribute to improving prognosis in unresectable pancreatic cancer.

In this study, NLR was found to be superior to the other factors tested in the multivariate and time-dependent ROC curve analyses. The cut-off value of the NLR level was 3.74 in this study, which is consistent with the level that ranged from 2.5 to 5.0 in the previous studies^9–12,25,26. The mechanism of the relationship between NLR and prognosis in patients with unresectable pancreatic cancer remains to be clarified. Neutrophils inhibit the immune response by lymphocytes, natural killer cells, or activated T cells^33,34, while lymphocytes reflect the immune response of the host to either infection or cancer. In addition, tumor-infiltrating lymphocytes are associated with better prognosis in patients with pancreatic ductal adenocarcinoma³⁵. This study revealed that a high NLR was significantly associated with the metastatic stage, and worse performance status. Collectively, our results may suggest that NLR reflects both the disease progression and patient condition in unresectable pancreatic cancer.

There are some limitations in this study. First, it is a retrospective and a single-center study with small number of patients. Therefore, a multicenter prospective validation is needed to validate our results. Second, we defined the cut-off value for NLR as 3.74, although the cut-off values for NLR vary from 2.5 to 5.0 in unresectable pancreatic cancer^9–12,25,27. The ideal cut-off value should be confirmed.

In conclusion, our results reveal that high NLR at the time of diagnosis could be an independent indicator of poor prognosis in patients with unresectable pancreatic cancer. Our findings suggest that a controlling factor for NLR could provide a novel therapeutic target for unresectable pancreatic cancer in the near future.

Methods

Study population

We retrospectively recruited 166 patients who had been diagnosed with pancreatic cancer from June 2006 to September 2018 at Fukuchiyama City Hospital. Of these 166 patients, we excluded 42 with resectable pancreatic cancer and 5 with borderline-resectable pancreatic cancer. Then, the data of a total of 119 patients with unresectable pancreatic cancer were analyzed in this study. The opt-out method was performed for obtaining informed consent due to the retrospective design. This retrospective study was consistent with the standards of the Declaration of Helsinki. This study was approved by the institutional review board of Fukuchiyama City Hospital (approval number: 1–44).

We collected patient clinical data on the age, body mass index, gender, tumor location, clinical stage, treatment, and prognoses. Clinical stage and their resectability criteria were determined based on the 7th edition of the Japan Pancreas Society guideline³⁶. In addition, we assessed ECOG-PS and the laboratory parameters at the time of diagnosis. Laboratory parameters, including the GPS, the modified GPS, NLR, PLR, CRP/Alb ratio, and PNI were evaluated using blood samples. Data on prognoses were confirmed by medical record review from October 2019 to March 2020.

For the GPS, the modified GPS, NLR, PLR, CRP/Alb ratio, and PNI values, we performed time-dependent ROC analysis, and calculated AUC for OS at the 6-month of follow-up. Subsequently, the cut-off values for continuous variables were determined using the Youden’s Index. OS was defined as the time from the date of diagnosis to the date of death or last follow-up. OS was evaluated between the two groups divided by the cut-off values in each prognostic score.

Univariate and multivariate analyses were used to determine the predictive factors of OS in patients with unresectable pancreatic cancer. The candidate factors analyzed were as follows; age, gender, tumor location, clinical stage, treatment, ECOG-PS, GPS, modified GPS, NLR, PLR, CRP/Alb ratio, and PNI. Finally, we assessed the relation between NLR and other clinical parameters. The parameters were as follows; age, gender, tumor location, clinical stage, treatment, ECOG-PS, GPS, modified GPS, PLR, CRP/Alb ratio, and PNI.

Statistical analysis

Data are shown as median and range. Time-dependent ROC analysis was conducted to determine the cut-off values for continuous variables. The OS rates were evaluated using Kaplan–Meier’s survival curves, and the log rank analysis was conducted to verify the significance of differences. Cox proportional hazards model analysis was conducted to calculate HR and 95% CI in the candidates of prognostic factors. A P value < 0.05 was statistically considered significant. All statistical analyses were performed using SPSS statistics version 26.0 (IBM Japan, Tokyo, Japan) and R software version 3.6.2.

Author contributions

Conception and design: N.I., T.O. and J.S.; Collection and assembly of data: N.I., T.O., T.H., T.O., M.T., H.S., K.O., T.H., T.T. and T.K.; Data analysis and interpretation: N.I., T.O. and J.S.; Manuscript preparation: N.I.; Revision of the manuscript: J.S., K.K., H.Y., Y.N. and Y.I.; Final approval of manuscript: All authors.

Competing interests

The authors declare no competing interests.